The disclosed systems and methods are configurable central nervous system (CNS) delivery solutions for therapeutics, such as genetic medicines. The systems and methods first infuse a therapeutic bolus within intrathecal space and subsequently infuse a flush fluid to move the therapeutic bolus rostrally toward a target area and achieve a desired spread in the spine and/or brain. The second location can be at a location caudal to the delivery location of the therapeutic bolus.

The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

This present invention discloses a dynamic dual-tracer PET reconstruction method based on a hybrid-loss 3D CNN, which selects a corresponding 3D convolution kernel for a 3D format of dual-tracer PET data, and performs feature extraction in a stereoscopic receptive field (down-sampling) and the reconstruction (up-sampling) process, which accurately reconstructs the three-dimensional concentration distributions of two different tracers from the dynamic sinogram. The method of the invention can better reconstruct the simultaneous-injection single-acquisition dual-tracer sinogram without any model constraints. The scanning time required for dual-tracer PET can be minimized based on the method of the present invention. Using this method, the raw sinogram data of dual tracers can be reconstructed into two volumetric individual images in a short time.

A method and system for combination therapy utilizing local drug delivery and radiotherapy at a target site of body tissue are provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A cargo may be delivered to the target site when exposed to the localized electric field. Radiotherapy is applied to the target site in combination with the local drug delivery.

Embodiments include a system for determining cardiovascular information for a patient. The system may include at least one computer system configured to receive patient-specific data regarding a geometry of the patient's heart, and create a three-dimensional model representing at least a portion of the patient's heart based on the patient-specific data. The at least one computer system may be further configured to create a physics-based model relating to a blood flow characteristic of the patient's heart and determine a fractional flow reserve within the patient's heart based on the three-dimensional model and the physics-based model.

The present invention is directed to a multi-angulated catheter and methods of using the multi-angulated catheter. The multi-angulated catheter is so dimensioned as to facilitate accessing the left ventricle from an arm of a patient. The multi-angulated catheter generally includes in order: (a) a coiled end; (b) a first straight portion having a first straight portion length; (c) a first shaft including a distal end connected to the first straight portion and a proximal end opposite the distal end, the first shaft and the first straight portion defining a first obtuse angle, the first shaft having a first shaft length; and (d) a second shaft connected to the first shaft on said proximal end. The catheter is flexible so as to afford being straightened when it is advanced over a guide wire. The catheter resiliently returns to a multi-angulated position after the guide wire is withdrawn.

Some embodiments provided herein relate to methods, systems and kits for providing consistent intracoronary administration of a biologic to subjects having diverse coronary anatomies. In some embodiments, the biologic is an adeno-associated virus serotype 1 (AAV1) vector encoding sarcoplasmic/endoplasmic reticulum ATPase 2a (SERCA2a) protein.

A drive assembly for a catheter procedure includes a body configured to receive a percutaneous device where the body has a first end and a second end. A distal pinch is configured to releasably engage the percutaneous device. A proximal pinch is positioned on the first end of the body and is configured to releasably engage the percutaneous device. A linear drive mechanism is coupled to the body and configured to move the body and the proximal pinch between a first position and a second position to cause linear movement of the percutaneous device along a longitudinal axis of the percutaneous device. A rotational drive mechanism is coupled to the second end of the body and is configured to rotate the body and the proximal pinch to cause the percutaneous device to rotate about the longitudinal axis of the percutaneous device.

A method for using CO.sub.2 as a contrast material in medical imaging procedures is disclosed. The method includes providing a source of pressurized CO.sub.2. The step of providing includes connecting the source of pressurized CO2 to a compressed gas unit for controlling delivery of the CO.sub.2. The method also includes regulating pressure of the CO.sub.2 delivered by the compressed gas unit, transmitting the pressurized CO.sub.2 from the compressed gas unit to a control valve assembly for delivery to a patient in controlled dosages, and sequentially processing the CO.sub.2 with the control valve assembly and delivering the CO.sub.2 to the patient as a contrast media.

The present invention relates to a device (1) for fractional flow reserve determination. The device (1) comprises a model generator (10) configured to generate a three-dimensional model (3DM) of a portion of an imaged vascular vessel tree (VVT) surrounding a stenosed vessel segment (SVS), based on a partial segmentation of the imaged vascular vessel tree (VVT). Further, the device comprises an image processor (20) configured to calculate a blood flow (Q) through the stenosed vessel segment (SVS) based on an analysis of a time-series of X-ray images of the vascular vessel tree (VVT). Still further, the device comprises a fractional-flow-reserve determiner (30) configured to determine a fractional flow reserve (FFR) based on the three-dimensional model (3DM) and the calculated blood flow.